KR930006674B1 - Packaged drug - Google Patents

Abstract

No content.

Description

Pharmaceutical package

1 is a partially broken perspective view showing an embodiment of the present invention drug label.

* Explanation of symbols for the main parts of the drawings

1: impregnated body 2: nonwoven fabric

The present invention relates to a drug label that wraps drugs such as insecticides, insect repellents, and repellents having room temperature volatiles. Recently, insecticides and insecticides of room temperature volatility have been widely used instead of insecticides made of a sublimable solid material. Such liquid insecticides and insecticides are generally impregnated with an impregnant according to their properties and conditions. There was a problem of staining the drug when it was put on other things, such as clothing.

Therefore, the impregnated body impregnated with the liquid insect repellent or insecticide is conventionally stored in a plastic container so as not to be in direct contact with other products. In addition, as another method for preventing stains on clothes, such as impregnant packaging materials such as liquid insect repellents and insecticides, non-woven fabrics have been laminated with a film of polyethylene or the like to prevent the drug from sticking to clothes. .

In addition, the pharmaceutical composition used at this time was limited to a liquid composition having a colorless or pale transparent property for the purpose of minimizing contamination, ie staining.

The method of storing the impregnating body impregnating and storing such a chemical solution in a plastic container is a method of preventing contamination by contact, but it is a highly reliable method, but it does not give sufficient satisfaction in view of the efficacy and effect of the chemical liquid. In other words, as the insecticide or insecticide is injected, it is important to secure a sufficient amount of volatilization and a corresponding volatilization area is required for a drug that is expected to have a certain effect.

However, in the case of plastic containers, there is a limit to the size and inadequate state naturally in economical or zero-road.

On the other hand, when a nonwoven fabric laminated with polyethylene or the like is used as a packaging material for a chemical liquid impregnation member, even if a thin film is laminated, the passage or permeation of gas, ie, a volatile drug, is remarkably prevented, and a sufficient effect cannot be expected. none. In addition, although it is designed to improve the gas permeability through processing such as drilling a plurality of holes in the film to be laminated, in this case, if the number of holes, that is, the opening is increased, it does not mean to laminate the plastic film. If the power is lowered, volatility is suppressed and it is difficult to expect a sufficient effect.

Moreover, in the case of the packaging material which laminated | stacked the plastic film on a nonwoven fabric, the manufacturing cost also becomes high. Another problem is that the color of the pharmaceutical composition can be clearly identified by the impregnation of the impregnation at the time of manufacture, and there are many advantages such as good design, but it is limited to colorless or light color.

In addition, the method of indicating when to end use due to color fading or fading is also restricted.

The object of the present invention is to solve the above-mentioned problems, to prevent staining of the chemical liquid from the impregnated body, thereby making it possible to color the chemical liquid and at the same time effectively with a sufficient volatilization amount without inhibiting the volatility of the drug. The present invention provides a pharmaceutical package that can volatilize a drug. In order to achieve this object, the pharmaceutical package of the present invention is a drug obtained by using liquid medicines such as insecticides, insect repellents, repellents, etc. having room temperature volatility as the main component, and color or gradually discoloring (including colorless to color change). The impregnant for impregnating and storing the composition is packaged with a nonwoven fabric having a weight of 35-70 g / m 2 (more preferably 40-60 g / m 2) to prevent the drug from being transferred from the impregnant to other materials through the nonwoven fabric. Since the nonwoven fabric has sufficient gas permeability, the effect is almost inferior. That is, according to the present invention, contamination by contact can be prevented without weakening the volatilization of the drug.

Here, the nonwoven fabric made of synthetic fibers such as polyester, polypuropene polyethylene, polyamide, polyurethane, and acryl may have micro voids, and it is not necessarily clear why it does not absorb the chemical liquid from the impregnant, but the main factor is It is believed that these synthetic fibers are derived from the surface state, such as the nature of the liquid communication and the size of the micropores of the nonwoven fabric.

Therefore, it is necessary to use a nonwoven fabric made of synthetic fibers having little or no affinity for the chemical liquid used. If the weight of the nonwoven fabric used is less than 35 g / m 2, the nonwoven fabric becomes thin and dense, and cannot sufficiently prevent contamination of the chemical liquid.

On the other hand, when it becomes larger than 70 g / m <2>, since a nonwoven fabric is thick and an eye becomes thin, it is not good because sufficient chemical vaporization amount cannot be secured.

In the present invention, as a medicament that can be used, various medicaments in liquid form having room temperature volatility can be used, for example, (R, S) -1-ethynyl-2-methylben-2-enyl (IR) -cis, trans Chrysan Rimat (hereinafter referred to as Beybaserin), 1-ethynyl-2-methyl-2-bentenyl-2, 2-zimethyl-3- (2 ', 2'-zigrod vinyl) -chic Ropropan-1-carboxylate, 1-ethynyl-2-methyl-2-bentinyl-2, 2-zimethyl-3- (2'-methyl-1'-propenyl) cyclopropane-1 -Organolines such as palceoid-based insecticides such as carboxylate, 1-ethynyl-2-methyl-2-bentinyl-2,2, 3,3-tetra methyl cyclopropane carboxylate, DDVP, and succinone Insect repellents such as fumed compounds, methyl methyl futalate, ethyl ethyl futalate, fujyl futalate, ethyl fumalate, N, N-ziethyl-m-tolamide, repellents, ethyl benzoate, saftol, isoprolol, Insect repellents such as Igenol, Cytonerone, Anetol, 1-Carbon, Citral, Citroneral, Nerol, Gera , The acetic acid Tina reel, acetamido hwenon, Tyr terpineol, menthone, benzoic acid benzyl, hwenil ethyl acetate, include insecticide, diffusers or the like of the flavoring, K, etc. PR day hydroxide, benzaldehyde, such as isoamyl, Yukari peutol. By using the above-mentioned various agents alone or in mixture of two or more thereof, it can be used as an insect repellent, insecticide, insect repellent, insect repellent, insect repellent, and the like.

Impregnants include paper, nonwovens, fabrics, wood, pulp, inorganic high molecular materials, inorganic porous materials (such as chelates, silica, zeolites), organic polymeric materials (cellulose, polyethylene, polyvinyl chloride, polypropylene, polyvinyl alcohol, Vinyl acetate-vinyl chloride copolymer, styrene-givinylbenzene copolymer, etc.), gelling materials (woom, carrageenan, starch, gelatin, arginic acid, etc.), sublimation materials (adamantane, cyclodicane, novolball, torimethyl Novolnan, end torimethogen novolnan, parazicrobenzene, naphtharene, camphor, and the like, and the like, and one or two or more thereof can be used in combination, and the shape of a mat, sheet, film It can be used in any chemical form such as shape, gel shape, powder, particle shape, tableting shape.

Various methods may be employed as a method of applying the medicament to the impregnated body. For example, in the case of a porous impregnated body, it may be impregnated by dropping coating, immersion coating, spray coating, printing, painting, etc. In the case of, the mixture with the drug can be prepared in a gel state, powder form, granule form or the like as it is.

As the impregnating body, an antioxidant, an ultraviolet absorber, a fixing agent, or the like can be added as necessary. The pharmaceutical composition used in the present invention also includes a pharmaceutical composition which gradually discolors, unlike the case where the drug itself has a color and colored by addition of a dye or the like.

This progressively discolored pharmaceutical composition is generally referred to as heat-sensitive, decompression nutrients using the perishability (impact action) of the drug as described above and the color development (development action) of the developer as described above. The color development mechanism of the compound causes color change.

For example, a brief description of the principle of color development is given to crystal baorelactone (CVL), a torifenyl methane-futalide-based dye.

Crystal Biot Racton Although it is colorless, the Lactone ring in Crystal Biot Racton is opened by the action of a developer (for example, bis phenoloxy A), and the color becomes blue as a crystal biot. On the other hand, when anperiodic agents (such as acetyls, amides, etc.) act, the reaction proceeds in reverse and becomes colorless to return to the Lactone ring.

The chromogenic pharmaceutical composition used in the present invention has applied this principle to the indication of drug efficacy, and the volatilization, ie, the liquid agent, is caused by the presence of a more volatile perishable agent in the above-mentioned electron donating color organic compound and the developer. In the presence of a sufficient amount, the vanishing effect of the medicament overcomes the action of the developer to suppress color development.

When the drug volatilizes and the residual rate decreases, the reaction with the developer and the electron-donating color organic compound starts to be colored, and when the drug is completely volatilized and does not remain, the color tone peculiar to the electron-donating color organic compound is applied. send.

Therefore, the reaction process and the volatilization process of the volatile permeable drug correspond to the color change of the composition, thereby visually recognizing the effect residual state and the end point of the volatile permeable drug.

The volatile perishant agent is good to be dissolved or melted uniformly with the electron donating colorimetric organic compound and / or the developer, but in the case of ball or egg soluble, a solvent may be used. As a solvent, it is good to dissolve the said chemical | medical agent, an electron-donating color organic compound, and a developer, and to just keep the melt gradually stable, For example, aliphatic hydrocarbons-aromatic, hydrocarbons, acetyl, ketone amides Etc. can be mentioned.

When the volatilization rate of a drug differs greatly from the volatilization rate of a solvent, it may become difficult, such as making it difficult to display accurate drug efficacy. In this case, what is necessary is just to use what the volatilization rate of a chemical | medical agent and a solvent does not differ significantly. The drug does not have to have even if it has own drug effect.

Examples of the electron donating colorimetric organic compounds used include torifenyl methane futalides, flanolanes, phenochazines, indrill futarides, spiropyranes, leuco-oramines, and odaminlactams. Marachite Greenlactone, Crystal Biot Racton, Romanmine Racton, 3-Gethylamino-6,8-jimethyl arolane, 3-cyclohekisyl amino-6-chlorofluoron, 2-methyl-6- (Np-Toryl-N-ethylamino) fluoroane, 3-ziethyl amino-6-methyl-7-chloro fluorolan, 3-jayel amino-7-methoxycyrroran, 3-ziethyl amino- 6-benzyl oxy hurolane, 3-giethyl amino-6-methyl hurolane, 3-giethyl amino-7-chloro hurolane, 3-giethyl amino-5-methyl-7- (N, N- paper Benzyl amino) huroran, 3-giethyl amino-6-methyl-7-anirino huoran, 3-giethyl amino-7- (N, N-zibenzyl amino) furan, 3-pyrotizino-6 -Methyl-7-anirinofuran, 3- (ziethyl amino) -7 (N, N-zibenzyl amino) furan, 3-piperidino-6-methyl-7-anirito furoran, 3,6-bis (ziethyl amino) lactam, 3- (N-Cyclohexyl-N-methylamino) 6-methyl-7-anirino hurorane 2,3-butyrene-6-g.m-butyl amino hurorane, 3-giethyl-7-cp -Tolzyno) furanan, 3-ziethylamino-7- (N-methylaniniro) furanan, 3-zimethylamino-6-methoxyhuranan, 1,2-benz-6-ziethyl Amino Hurolanes, 3,6-Jiethoxy Hurolanes, 3-Glymethyl Amino-6-Methyl-7-Cr Frutholane, 1,2-Benz-6-Gethyl Ethyl Aurofuran, N-Phenillodamine Rack Top , 2- [3,6-bis (ziethyl amino) -9- (0-chloronilino) chianthyl] benzoic acid lactam, 2- (phenyl amino ethanezilidene) -3,3-zimethyl indrin, 8'-methoxy-N-3,3-trimethyl indrinobenzos pyropyran, N-phenyl amino ethanezilidene) -3,3-torrimethyl indrinobenz pyropyran, 1,3,3-trimethyl ind Reno -2,2 ' -Spiro-6'-nitro-8'-methoxy benzpyran, 1,3,3-trimethyl-indrino-7'-chloro-β-naft spiropyran, G-β-naft spiropyran, benz -beta-naphtho isospyrropyran, chisant-beta-naftspiropyran, N-acetio-lamin, N- phenylo- lamin, rhodamine B-lactam, benz irroico methylene ball-methyl leuco methylene bull- And ethyl leuco methylene fluorine-methoxy benzoircoicomethyl and the like, and the use thereof may be used alone or in combination of two or more thereof.

The electron donating color organic compounding does not volatilize in the state of use of the pharmaceutical composition, that is, if it is nonvolatile or egg volatile, various conventionally known compounds can be used.

The electron-donating color-changing rainy season compounds are colorless or pale color alone, but color develops when a developer is present.

In the present invention, the developer used is exemplified by 2,2-bis (4'-hydroxyphenyl) propane and 3-3'-thiojitropionic acid gimyristyl 2,2'-methylenebis (4- Chlorophenol), 4,4'-methylenebis-2-6-zi-t-butylphenone, 2,4,6-tris (3'5'-zi-t-butyl-4'-hydroxybenzyl) mesh Tylene, 4,4'-thiophenenol, 4-4'-bis (4hydroxyphenyl) thruhorn, butylidenebis-t-butyl-m-cresol, p-phenylphenol, 1,1,3- Tris (2-methyl-4-hydroxy-5-t-butylphenyl) butane, 3,5-di-t-butylcatechol, catechol, pt-butylcatechol, methyl omezao acid , Sarithylic acid, sarithynil anilide, sarithylic acid p-ocylphenyl, sarithylic acid pt-butylphenyl, 2-hydroxy-4-methoxybenzophenone, 2,2 ', 4,4'-tetrahydroxybenzo Phenone, 2,2'-zihydroxy-4-methoxybenzophenone, 2,2'-zihydroxy-4,4'-zimethoxybenzophenone, 2,4-zihydroxy benzophenone, 2-hydroxy Oxy-4-n-octoxybenzophenone, β-naphthol, p-cresol, hydroxynon, Butyl hydroxyanisole, 6-t-butyl-2,4-quisylenol, p-hydroxy benzyl alcohol, ot-butylphenol, t-butylhydroxyquinone, 2-t-butyl-6-methylphenol, 2 , 5-gi-t-butylhydroxyquinone, propyl hydroxybenzoic acid, 1,2,4-trihydroxybenzene, 1,2,3-benzotriazole, and the like. Various conventional color developer of non-volatile or hard volatility can be used.

The developer may be used alone or in combination of two or more thereof. The division of the volatile perishable agent, the electron donating color organic compound and the developer is usually sufficient by weight ratio of the drug: the electron donating color organic compound: the color rendering agent = 100: 0.1-50: 0,01-100. A good range is 100: 0.2-30: 0,1-50.

Moreover, when the permeability of the said chemical | medical agent is weak, the developer having a weak action can be used, but the permeability of the said chemical | medical agent may be compensated for using a perishable solvent. As the color tone obtained by the color of the electron donating color organic compound, almost any color is obtained in red, black, blue, green, purple, orange, yellow, and brown, so that the color of the electron donating color organic compound is appropriate for the drug used. By selecting a color developer, and a solvent, if necessary, a desired color tone, color concentration and color change period can be expected.

In addition, discoloration from colored to colored is possible by adding colorants such as general oil-soluble dyes.

청자색

적자색으로 변색이 된다.One example of oil-soluble dye eisenpyrone-GNH, 1 part of repellent N, N-giethyl-m-toriamide, 1 part of electron-donating color organic compound NC-R-1 (furan-based compound), string When the mixed solution of the colorant bisfenol A2 part is applied to a linta mat and left at room temperature, the solution is colored blue by volatilization of the repellent.

Blue purple

It turns red.

Hereinafter, the present invention will be described in detail with reference to Examples and Comparative Examples.

Example 1-6

Comparative Example 1-3

A nonwoven fabric 2 shown in Table 1 is shown in Table 1, where the agglomerating body 1 obtained by coating and immersing a mixed solution of 100 parts of paperlin and 1 part of an oily blue pigment on a 6 cm x 8 cm x 2 mm thick mat is made of pulp. Packaging is carried out to obtain a spray-proof package.

TABLE 1

Each obtained room insecticide package was covered with a white film, and it sealed again with the film which laminated | stacked the aluminum foil. This is maintained under the conditions of 40 ° C. to gradually control the transition of the pigment into the nonwoven fabric and the white cloth.

The results are shown in Table-2.

TABLE 2

In addition, the meaning of each code | symbol in the said table is as follows.

-: No implementation confirmation, ±: Somewhat implementation, +: Implementation confirmation, ++, +++: Certainly implementation

As can be seen from the results shown in Table 2 above, when the weight as in Comparative Example 1 is less than 35 g / m 2, since the eyes are thin, there is a direct contact between the white cloth and the impregnated body and the transfer of the pigment, that is, the transfer of the chemical liquid. This was recognized.

On the other hand, if the weight is in the range of 35-70 g / m2 as in the case of the embodiment 1-6, a slight shift to the nonwoven fabric is recognized, but no further shift is made, and the shift to the white cloth is not recognized even after a long period of time. Did.

On the other hand, when a rayon nonwoven fabric is used as a nonwoven table (Comparative Example 2) and when a mixed cloth of rayon and polypropylene is used (Comparative Example-3), the weight is not limited to the above range, Significant implementation was recognized.

EXAMPLES 7,8

[Comparative Examples 4 and 5]

300 mg of paperlin was coated on a 6 cm x 8 cm x 2 mm thick pulp mat, and then packaged with a nonwoven fabric as shown in Table 3 to obtain a room and insecticide package.

Each obtained antiseptic and insecticide package was attached to a container (about 750 L in volume), and the drug preservation rate in the mat was measured gradually. The results are shown in Table-4.

TABLE 4

As in the above results, in the case of the laminated rayon nonwoven fabric, volatilization of the drug is remarkably suppressed, and the volatilization of the drug is suppressed even when the weight of the nonwoven fabric is large as in Comparative Example (4). , Sufficient effect is not obtained.

On the other hand, when a synthetic fiber nonwoven fabric having a certain range of weight specified in the present invention is used, sufficient chemicals are volatilized for about 6 months, and above all, contact of the chemicals between them is evident from the results shown in Table-2. Contamination from migration is also prevented.

Example 9-20

Comparative Example 6-29

The impregnated body obtained by coating and impregnating 300 mg of the composition of the prescription shown in Table 5 with a room temperature volatile agent: leuco dye: colorant = 1: 0.02: 0,05 on a pulp mat of 6 cm x 8 cm x 2 mm thickness. After packing 1 with various nonwoven fabrics shown in the table, it sealed, stored at 40 degreeC for 6 months, and took out in the container, and observed the color change after that.

TABLE 5

The results are shown in Table-6.

The meanings of the symbols in the table are as follows.

-… … Color change is not recognized at all

±… … Slightly discoloration

+… … discoloration

++… … Widely clear discoloration

TABLE 6

As can be seen from the above results, in Example 9-20, the impregnated body is discolored in a unique color of each dye at 4-6 months after volatilization, and the nonwoven fabric containing it has no color change since there is no transition of the chemical solution. . On the other hand, in Comparative Example 6-29, the nonwoven fabric is also discolored in parallel with the discoloration of each impregnating body.

This is because the chemical moves from the impregnation body toward the nonwoven fabric. As described above, the pharmaceutical package of the present invention is made from a synthetic resin of polyester, polypropylene, and nylon, which is impregnated with a liquid drug having room temperature volatility and lacks in affinity with a chemical solution. Because it was packaged with nonwoven fabric, it was possible to volatilize the drug with sufficient volatilization over a long period of time, and at the same time, the drug was contaminated by contacting other substances through the nonwoven fabric from the impregnating body.

For this reason, it is possible to use a composition obtained by coloring or gradually discoloring, to clearly determine whether the pharmaceutical composition is impregnated into the impregnating agent at the time of manufacture, and to clearly recognize the end point of the drug. There are many advantages in manufacturing and use.

Claims (2)

A pharmaceutical package comprising a synthetic fiber nonwoven fabric having a weight of 35-70 g / m 2 containing an impregnating agent containing a chromophoric composition obtained by discoloring or gradually discoloring with a volatile drug as a main component. The pharmaceutical package according to claim 1, wherein the synthetic fiber nonwoven fabric is made of polycitelel, polypropylene, polyethylene, polyamide, polyurethane, or acrylic fiber.

Images